Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.
Adolescent
Adult
Aged
Aged, 80 and over
Biopsy, Fine-Needle
DNA Mutational Analysis
Exons
/ genetics
Female
Humans
Male
Middle Aged
PAX8 Transcription Factor
/ genetics
Prospective Studies
Proto-Oncogene Proteins B-raf
/ genetics
Thyroid Cancer, Papillary
/ diagnosis
Thyroid Neoplasms
/ diagnosis
Thyroid Nodule
/ diagnosis
Young Adult
cyto-histological correlation
fine needle cytology
indeterminate nodules
mutational analysis
papillary thyroid carcinoma
thyroid cancer treatment
ultrasound features
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
26
03
2019
revised:
28
08
2019
accepted:
29
08
2019
pubmed:
5
9
2019
medline:
15
9
2020
entrez:
5
9
2019
Statut:
ppublish
Résumé
Fine needle cytology (FNC) is the first-line diagnostic method to determine the benign or malignant nature of thyroid nodules. The gray zone of cytological classifications remains, however, a crucial and challenging area for cytopathologists. In the present study, 141 thyroid cytological samples, with ultrasonographic suspicious features, have been prospectively analysed. Molecular analyses were performed by an innovative technology using two multiplex PCRs for the amplification of BRAF, N-H-K-RAS and RET exon genes. RNA samples were studied for RET/PTC1 and RET/PTC3 rearrangements by PCR amplification, and the conditions were set-up to study, with a single experiment, both wild-type PAX8 and PAX8/PPARɣ rearrangements. In total, 111 samples were examined for BRAF, N-H-KRAS and RET genes. An ultrasonographic, cytological and molecular correlation was also carried out in an attempt to suggest a possible way to manage the patients with thyroid nodules. Cyto-histological correlation was available in 115 cases, and it was used to verify the global diagnostic accuracy of this combined approach. According to the histopathological diagnosis, FNC accuracy was 100% for TIR5 and metastases; 89% for TIR4; 84% for TIR3A and 58% for TIR3B. About 11% of the studied samples showed either RET-PTC1 or RET/PTC3 chromosomal rearrangements, and only one sample simultaneously presented RET/PTC1 and RET/PTC3 rearrangements. PAX8/PPARɣ rearrangement was found in 6% of the samples. A multidisciplinary approach to the thyroid is therefore necessary to develop innovative methods suitable for an improved diagnostic and prognostic definition of thyroid cancer.
Identifiants
pubmed: 31483883
doi: 10.1111/cen.14089
pmc: PMC6972562
doi:
Substances chimiques
PAX8 Transcription Factor
0
PAX8 protein, human
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-859Informations de copyright
© 2019 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
Eur J Endocrinol. 2013 Apr 15;168(5):649-55
pubmed: 23416955
Oncotarget. 2018 Apr 10;9(27):19255-19262
pubmed: 29721199
Thyroid. 2012 Oct;22(10):1025-30
pubmed: 23025542
Diagn Cytopathol. 2008 Feb;36(2):104-12
pubmed: 18181183
J Endocrinol Invest. 2014 Jun;37(6):593-9
pubmed: 24789536
Cytopathology. 2017 Dec;28(6):482-487
pubmed: 29094776
Arch Pathol Lab Med. 2006 Apr;130(4):452-5
pubmed: 16594737
Curr Opin Oncol. 2003 Jan;15(1):66-70
pubmed: 12490764
J Clin Endocrinol Metab. 2009 May;94(5):1748-51
pubmed: 19276237
J Clin Endocrinol Metab. 2011 Jul;96(7):2016-26
pubmed: 21593119
Virchows Arch. 2018 Nov;473(5):639-643
pubmed: 29860621
Endocr Relat Cancer. 2005 Jun;12(2):305-17
pubmed: 15947105
JAMA Oncol. 2019 Feb 1;5(2):204-212
pubmed: 30419129
Thyroid. 2016 Apr;26(4):562-72
pubmed: 26756476
PLoS One. 2014 Oct 17;9(10):e109822
pubmed: 25330015
Cancer Cytopathol. 2016 May;124(5):340-9
pubmed: 26749005
Histopathology. 2005 Oct;47(4):391-401
pubmed: 16178894
Endocr Pathol. 2015 May;26(2):140-4
pubmed: 25771987
Head Neck. 2016 Feb;38(2):309-15
pubmed: 25244250
Clin Cancer Res. 2013 May 1;19(9):2283-8
pubmed: 23422095
Diagn Cytopathol. 2008 Jun;36(6):425-37
pubmed: 18478609
Int J Clin Exp Pathol. 2015 May 01;8(5):5793-7
pubmed: 26191299
Arch Pathol Lab Med. 2011 May;135(5):569-77
pubmed: 21526955
Endocr Pathol. 2005 Fall;16(3):163-72
pubmed: 16299399
Clin Endocrinol (Oxf). 2019 Dec;91(6):851-859
pubmed: 31483883
Oncotarget. 2017 Jul 25;8(30):49351-49358
pubmed: 28537891
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Gland Surg. 2018 Aug;7(Suppl 1):S19-S29
pubmed: 30175060
Ann Intern Med. 2013 Sep 3;159(5):325-32
pubmed: 24026318
Surg Oncol Clin N Am. 2016 Jan;25(1):1-16
pubmed: 26610771
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Lancet Oncol. 2008 Jun;9(6):543-9
pubmed: 18495537
Clin Endocrinol (Oxf). 1999 Oct;51(4):509-15
pubmed: 10583320
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
BMC Surg. 2013;13 Suppl 2:S44
pubmed: 24267151
J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7
pubmed: 21880806